Literature DB >> 20816997

Bacteriophage treatment significantly reduces viable Clostridium difficile and prevents toxin production in an in vitro model system.

Emma Meader1, Melinda J Mayer, Michael J Gasson, Dietmar Steverding, Simon R Carding, Arjan Narbad.   

Abstract

Clostridium difficile is primarily a nosocomial pathogen, causing thousands of cases of antibiotic-associated diarrhoea in the UK each year. In this study, we used a batch fermentation model of a C. difficile colonised system to evaluate the potential of a prophylactic and a remedial bacteriophage treatment regime to control the pathogen. It is shown that the prophylaxis regime was effective at preventing the growth of C. difficile (p = <0.001) and precluded the production of detectable levels of toxins A and B. The remedial treatment regime caused a less profound and somewhat transient decrease in the number of viable C. difficile cells (p = <0.0001), but still resulted in a lower level of toxin production relative to the control. The numbers of commensal bacteria including total aerobes and anaerobes, Bifidobacterium sp., Bacteroides sp., Lactobacillus sp., total Clostridium sp., and Enterobacteriaceae were not significantly decreased by this therapy, whereas significant detrimental effects were observed with metronidazole treatment. Our study indicates that phage therapy has potential to be used for the control of C. difficile; it highlights the main benefits of this approach, and some future challenges. Copyright Â
© 2010 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20816997     DOI: 10.1016/j.anaerobe.2010.08.006

Source DB:  PubMed          Journal:  Anaerobe        ISSN: 1075-9964            Impact factor:   3.331


  27 in total

1.  Current Status of Nonantibiotic and Adjunct Therapies for Clostridium difficile Infection.

Authors:  Nuntra Suwantarat; David A Bobak
Journal:  Curr Infect Dis Rep       Date:  2011-02       Impact factor: 3.725

2.  Using a Novel Lysin To Help Control Clostridium difficile Infections.

Authors:  Qiong Wang; Chad W Euler; Aurelia Delaune; Vincent A Fischetti
Journal:  Antimicrob Agents Chemother       Date:  2015-09-21       Impact factor: 5.191

Review 3.  Models for the study of Clostridium difficile infection.

Authors:  Emma L Best; Jane Freeman; Mark H Wilcox
Journal:  Gut Microbes       Date:  2012-03-01

Review 4.  Battling Enteropathogenic Clostridia: Phage Therapy for Clostridioides difficile and Clostridium perfringens.

Authors:  Jennifer Venhorst; Jos M B M van der Vossen; Valeria Agamennone
Journal:  Front Microbiol       Date:  2022-06-13       Impact factor: 6.064

5.  Recombinational switching of the Clostridium difficile S-layer and a novel glycosylation gene cluster revealed by large-scale whole-genome sequencing.

Authors:  Kate E Dingle; Xavier Didelot; M Azim Ansari; David W Eyre; Alison Vaughan; David Griffiths; Camilla L C Ip; Elizabeth M Batty; Tanya Golubchik; Rory Bowden; Keith A Jolley; Derek W Hood; Warren N Fawley; A Sarah Walker; Timothy E Peto; Mark H Wilcox; Derrick W Crook
Journal:  J Infect Dis       Date:  2012-11-29       Impact factor: 5.226

Review 6.  Clostridioides difficile phage biology and application.

Authors:  Joshua Heuler; Louis-Charles Fortier; Xingmin Sun
Journal:  FEMS Microbiol Rev       Date:  2021-09-08       Impact factor: 16.408

7.  As Clear as Mud? Determining the Diversity and Prevalence of Prophages in the Draft Genomes of Estuarine Isolates of Clostridium difficile.

Authors:  Katherine R Hargreaves; James R Otieno; Anisha Thanki; Matthew J Blades; Andrew D Millard; Hilary P Browne; Trevor D Lawley; Martha R J Clokie
Journal:  Genome Biol Evol       Date:  2015-05-27       Impact factor: 3.416

8.  A Taxonomic Review of Clostridium difficile Phages and Proposal of a Novel Genus, "Phimmp04likevirus".

Authors:  Katherine R Hargreaves; Martha R J Clokie
Journal:  Viruses       Date:  2015-05-21       Impact factor: 5.048

9.  Synergistic action of gentamicin and bacteriophage in a continuous culture population of Staphylococcus aureus.

Authors:  Amy E Kirby
Journal:  PLoS One       Date:  2012-11-30       Impact factor: 3.240

Review 10.  Clostridium difficile phages: still difficult?

Authors:  Katherine R Hargreaves; Martha R J Clokie
Journal:  Front Microbiol       Date:  2014-04-28       Impact factor: 5.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.